SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '5e8y'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_A_STIA201_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.78A 1iepA-5e8yA:
18.8		 1iepA-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_B_STIB202_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
GLY A 331
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
 0.79A 1iepB-5e8yA:
18.8		 1iepB-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M17_A_AQ4A999_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
LYS A 277
GLU A 290
LEU A 323
THR A 325
GLY A 331
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
None
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.49A 1m17A-5e8yA:
26.6		 1m17A-5e8yA:
25.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1OPJ_A_STIA3_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.9A)
 0.67A 1opjA-5e8yA:
6.3		 1opjA-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1OPJ_B_STIB4_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
GLY A 331
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
 0.87A 1opjB-5e8yA:
18.1		 1opjB-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1T46_A_STIA3_1
(HOMO SAPIENS V-KIT
HARDY-ZUCKERMAN 4
FELINE SARCOMA VIRAL
ONCOGENE HOMOLOG)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
LYS A 277
GLU A 290
THR A 325
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.57A 1t46A-5e8yA:
25.1		 1t46A-5e8yA:
28.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UWH_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 ALA A 275
GLU A 290
LEU A 305
THR A 325
LEU A 361
HIS A 377
 STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
None
 0.81A 1uwhA-5e8yA:
24.9		 1uwhA-5e8yA:
27.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UWH_B_BAXB1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
LYS A 277
GLU A 290
LEU A 305
THR A 325
LEU A 361
HIS A 377
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
None
 0.80A 1uwhB-5e8yA:
24.8		 1uwhB-5e8yA:
27.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UWJ_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
GLU A 290
LEU A 305
THR A 325
LEU A 361
HIS A 377
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
None
 0.81A 1uwjA-5e8yA:
6.7		 1uwjA-5e8yA:
27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UWJ_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
GLU A 290
LEU A 305
THR A 325
SER A 401
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
 1.12A 1uwjA-5e8yA:
6.7		 1uwjA-5e8yA:
27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UWJ_B_BAXB1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
GLU A 290
LEU A 305
THR A 325
LEU A 361
HIS A 377
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
None
 0.80A 1uwjB-5e8yA:
6.5		 1uwjB-5e8yA:
27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1YA4_B_CTXB1283_1
(CES1 PROTEIN)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		4 / 7 LEU A 361
GLY A 357
LEU A 299
PRO A 367
 None
 0.92A 1ya4B-5e8yA:
undetectable		 1ya4B-5e8yA:
23.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2EVA_A_ADNA498_1
(TAK1 KINASE - TAB1
CHIMERA FUSION
PROTEIN)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 11 VAL A 250
GLY A 251
GLY A 253
VAL A 258
ALA A 275
LEU A 386
 STU  A 601 (-3.9A)
STU  A 601 (-2.9A)
STU  A 601 ( 3.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-3.9A)
 0.65A 2evaA-5e8yA:
26.6		 2evaA-5e8yA:
27.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FUM_D_MIXD3539_1
(PROBABLE
SERINE/THREONINE-PRO
TEIN KINASE PKNB)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 GLY A 251
GLY A 253
VAL A 258
ALA A 275
LYS A 381
ASN A 384
 STU  A 601 (-2.9A)
STU  A 601 ( 3.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
None
STU  A 601 ( 4.9A)
 0.58A 2fumD-5e8yA:
23.6		 2fumD-5e8yA:
24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
LYS A 277
GLU A 290
THR A 325
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.68A 2gqgA-5e8yA:
22.1		 2gqgA-5e8yA:
27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_B_STIB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.82A 2hyyB-5e8yA:
18.9		 2hyyB-5e8yA:
27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_C_STIC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.72A 2hyyC-5e8yA:
19.0		 2hyyC-5e8yA:
27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2ITO_A_IREA2020_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
LYS A 277
GLU A 290
LEU A 323
THR A 325
GLY A 331
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
None
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.52A 2itoA-5e8yA:
25.9		 2itoA-5e8yA:
25.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2ITY_A_IREA2020_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		9 / 12 GLY A 251
VAL A 258
ALA A 275
LYS A 277
GLU A 290
LEU A 323
THR A 325
GLY A 331
LEU A 386
 STU  A 601 (-2.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
None
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.70A 2ityA-5e8yA:
25.7		 2ityA-5e8yA:
25.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2ITY_A_IREA2020_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		8 / 12 VAL A 258
ALA A 275
LYS A 277
GLU A 290
LEU A 323
THR A 325
GLY A 331
ASP A 397
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
None
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.0A)
 0.71A 2ityA-5e8yA:
25.7		 2ityA-5e8yA:
25.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2ITZ_A_IREA2021_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
LYS A 277
GLU A 290
THR A 325
GLY A 331
ASP A 397
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.0A)
 0.74A 2itzA-5e8yA:
21.1		 2itzA-5e8yA:
25.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2ITZ_A_IREA2021_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
LYS A 277
GLU A 290
THR A 325
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.63A 2itzA-5e8yA:
21.1		 2itzA-5e8yA:
25.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2OAX_D_SNLD4001_2
(MINERALOCORTICOID
RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		4 / 5 LEU A 452
LEU A 380
CYH A 520
THR A 518
 None
 1.18A 2oaxD-5e8yA:
undetectable		 2oaxD-5e8yA:
20.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WGJ_A_VGHA2346_1
(HEPATOCYTE GROWTH
FACTOR RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 GLY A 251
VAL A 258
ALA A 275
LEU A 305
GLY A 331
ASP A 397
 STU  A 601 (-2.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 (-3.5A)
STU  A 601 (-3.0A)
 0.70A 2wgjA-5e8yA:
24.1		 2wgjA-5e8yA:
25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y69_P_CHDP1265_0
(CYTOCHROME C OXIDASE
POLYPEPTIDE 7A1
CYTOCHROME C OXIDASE
SUBUNIT 3)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		4 / 5 PHE A 255
PHE A 279
LEU A 323
PHE A 294
 None
 1.09A 2y69P-5e8yA:
2.7
2y69W-5e8yA:
undetectable		 2y69P-5e8yA:
20.43
2y69W-5e8yA:
14.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3ABM_P_CHDP1271_0
(CYTOCHROME C OXIDASE
POLYPEPTIDE 7A1
CYTOCHROME C OXIDASE
SUBUNIT 3)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		4 / 5 PHE A 255
PHE A 279
LEU A 323
PHE A 294
 None
 1.17A 3abmP-5e8yA:
2.4
3abmW-5e8yA:
undetectable		 3abmP-5e8yA:
20.43
3abmW-5e8yA:
11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AG3_C_CHDC271_0
(CYTOCHROME C OXIDASE
POLYPEPTIDE 7A1
CYTOCHROME C OXIDASE
SUBUNIT 3)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		4 / 5 PHE A 255
PHE A 279
LEU A 323
PHE A 294
 None
 1.26A 3ag3C-5e8yA:
2.0
3ag3J-5e8yA:
undetectable		 3ag3C-5e8yA:
20.43
3ag3J-5e8yA:
11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3APX_A_Z80A190_1
(ALPHA-1-ACID
GLYCOPROTEIN 2)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 PHE A 474
VAL A 491
GLU A 428
ARG A 528
ALA A 451
 None
 1.19A 3apxA-5e8yA:
undetectable		 3apxA-5e8yA:
23.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3BBT_D_FMMD91_1
(RECEPTOR
TYROSINE-PROTEIN
KINASE ERBB-4)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
LEU A 323
THR A 325
GLY A 331
LEU A 386
PHE A 398
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
None
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
None
 0.80A 3bbtD-5e8yA:
19.8		 3bbtD-5e8yA:
25.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3BBT_D_FMMD91_1
(RECEPTOR
TYROSINE-PROTEIN
KINASE ERBB-4)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
LYS A 277
LEU A 323
THR A 325
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
None
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.71A 3bbtD-5e8yA:
19.8		 3bbtD-5e8yA:
25.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3C7Q_A_XINA1172_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 GLY A 251
ALA A 275
LYS A 277
PHE A 327
GLY A 331
LEU A 386
CYH A 396
 STU  A 601 (-2.9A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
STU  A 601 (-3.2A)
 0.77A 3c7qA-5e8yA:
23.5		 3c7qA-5e8yA:
29.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_A_NILA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 ALA A 275
ILE A 293
THR A 325
GLY A 331
HIS A 377
LEU A 386
 STU  A 601 (-3.1A)
None
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
None
STU  A 601 (-3.9A)
 1.19A 3cs9A-5e8yA:
18.6		 3cs9A-5e8yA:
27.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_C_NILC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 ALA A 275
ILE A 293
THR A 325
HIS A 377
ASP A 397
 STU  A 601 (-3.1A)
None
STU  A 601 ( 3.7A)
None
STU  A 601 (-3.0A)
 0.93A 3cs9C-5e8yA:
8.5		 3cs9C-5e8yA:
27.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_D_NILD600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 ALA A 275
ILE A 293
THR A 325
PHE A 327
GLY A 331
HIS A 377
 STU  A 601 (-3.1A)
None
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
None
 1.36A 3cs9D-5e8yA:
18.7		 3cs9D-5e8yA:
27.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3EYG_A_MI1A1_1
(TYROSINE-PROTEIN
KINASE)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		8 / 12 GLY A 251
GLY A 253
VAL A 258
ALA A 275
LYS A 277
ASN A 384
LEU A 386
ASP A 397
 STU  A 601 (-2.9A)
STU  A 601 ( 3.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 4.9A)
STU  A 601 (-3.9A)
STU  A 601 (-3.0A)
 0.70A 3eygA-5e8yA:
28.3		 3eygA-5e8yA:
27.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3G0F_A_B49A9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 11 VAL A 258
ALA A 275
THR A 325
GLY A 331
LEU A 386
CYH A 396
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
STU  A 601 (-3.2A)
 0.76A 3g0fA-5e8yA:
13.6		 3g0fA-5e8yA:
27.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3G0F_B_B49B9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 10 VAL A 258
ALA A 275
THR A 325
GLY A 331
LEU A 386
CYH A 396
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
STU  A 601 (-3.2A)
 0.61A 3g0fB-5e8yA:
24.2		 3g0fB-5e8yA:
27.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3HEC_A_STIA1_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 VAL A 250
ALA A 275
LYS A 277
GLU A 290
THR A 325
 STU  A 601 (-3.9A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
 0.59A 3hecA-5e8yA:
16.4		 3hecA-5e8yA:
25.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3HEG_A_BAXA1_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 VAL A 250
ALA A 275
LYS A 277
GLU A 290
THR A 325
 STU  A 601 (-3.9A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
 0.80A 3hegA-5e8yA:
19.7		 3hegA-5e8yA:
25.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3HEG_A_BAXA1_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 VAL A 250
VAL A 258
ALA A 275
LYS A 277
THR A 325
 STU  A 601 (-3.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.7A)
 0.65A 3hegA-5e8yA:
19.7		 3hegA-5e8yA:
25.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_A_STIA2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.74A 3k5vA-5e8yA:
18.4		 3k5vA-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_B_STIB2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.74A 3k5vB-5e8yA:
24.2		 3k5vB-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LFA_A_1N1A361_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 8 VAL A 250
ALA A 275
LYS A 277
GLU A 290
LEU A 323
THR A 325
 STU  A 601 (-3.9A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
None
STU  A 601 ( 3.7A)
 0.56A 3lfaA-5e8yA:
19.2		 3lfaA-5e8yA:
25.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MIY_B_B49B2_1
(TYROSINE-PROTEIN
KINASE ITK/TSK)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 9 ALA A 275
LYS A 277
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.70A 3miyB-5e8yA:
25.3		 3miyB-5e8yA:
27.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MS9_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.9A)
 0.77A 3ms9A-5e8yA:
18.8		 3ms9A-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MS9_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.79A 3ms9B-5e8yA:
18.8		 3ms9B-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.9A)
 0.79A 3mssA-5e8yA:
19.0		 3mssA-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_C_STIC1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
GLU A 290
THR A 325
PHE A 327
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.9A)
 0.80A 3mssC-5e8yA:
18.9		 3mssC-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_D_STID1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 ALA A 275
GLU A 290
THR A 325
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.70A 3mssD-5e8yA:
18.9		 3mssD-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_D_STID1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 ALA A 275
ILE A 293
THR A 325
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-3.1A)
None
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.91A 3mssD-5e8yA:
18.9		 3mssD-5e8yA:
29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
LYS A 277
LEU A 305
THR A 325
PHE A 398
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
 0.81A 3og7A-5e8yA:
25.0		 3og7A-5e8yA:
27.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OHT_A_1N1A1000_1
(P38A)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 250
GLY A 251
VAL A 258
ALA A 275
LYS A 277
THR A 325
LEU A 386
 STU  A 601 (-3.9A)
STU  A 601 (-2.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.9A)
 1.00A 3ohtA-5e8yA:
4.6		 3ohtA-5e8yA:
24.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OHT_B_1N1B1000_1
(P38A)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 GLY A 251
VAL A 258
ALA A 275
LYS A 277
THR A 325
LEU A 386
 STU  A 601 (-2.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.9A)
 0.96A 3ohtB-5e8yA:
4.6		 3ohtB-5e8yA:
24.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3ZBF_A_VGHA3000_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ROS)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 ALA A 275
LEU A 305
GLY A 331
LEU A 386
ASP A 397
 STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
STU  A 601 (-3.0A)
 0.52A 3zbfA-5e8yA:
15.1		 3zbfA-5e8yA:
26.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3ZOS_A_0LIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		8 / 12 ALA A 275
LYS A 277
GLU A 290
THR A 325
LEU A 361
HIS A 377
ARG A 378
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
None
None
STU  A 601 (-3.9A)
 0.78A 3zosA-5e8yA:
23.7		 3zosA-5e8yA:
26.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		8 / 12 ALA A 275
LYS A 277
GLU A 290
THR A 325
LEU A 361
HIS A 377
ARG A 378
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
None
None
STU  A 601 (-3.9A)
 0.79A 3zosB-5e8yA:
23.8		 3zosB-5e8yA:
26.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A83_A_DXCA1160_0
(MAJOR POLLEN
ALLERGEN BET V 1-A)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 PRO A 498
PHE A 474
LEU A 430
ALA A 451
SER A 449
 None
 1.40A 4a83A-5e8yA:
undetectable		 4a83A-5e8yA:
19.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A84_A_DXCA1161_0
(MAJOR POLLEN
ALLERGEN BET V 1-A)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 PRO A 498
PHE A 474
LEU A 430
ALA A 451
SER A 449
 None
 1.37A 4a84A-5e8yA:
undetectable		 4a84A-5e8yA:
18.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AG8_A_AXIA2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		8 / 12 VAL A 258
ALA A 275
LYS A 277
GLU A 290
PHE A 327
GLY A 331
LEU A 386
CYH A 396
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
STU  A 601 (-3.2A)
 0.75A 4ag8A-5e8yA:
24.7		 4ag8A-5e8yA:
29.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AGC_A_AXIA2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
LYS A 277
GLY A 331
LEU A 386
CYH A 396
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
STU  A 601 (-3.2A)
 0.46A 4agcA-5e8yA:
24.3		 4agcA-5e8yA:
27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AGD_A_B49A2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 11 ALA A 275
LYS A 277
PHE A 327
GLY A 331
LEU A 386
CYH A 396
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
STU  A 601 (-3.2A)
 0.77A 4agdA-5e8yA:
18.8		 4agdA-5e8yA:
27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ASD_A_BAXA1500_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		8 / 12 VAL A 258
ALA A 275
LYS A 277
GLU A 290
PHE A 327
GLY A 331
LEU A 361
HIS A 377
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
None
None
 0.75A 4asdA-5e8yA:
24.3		 4asdA-5e8yA:
27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4BKJ_B_STIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
GLU A 290
ILE A 293
THR A 325
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
None
STU  A 601 ( 3.7A)
STU  A 601 (-3.9A)
 0.99A 4bkjB-5e8yA:
23.8		 4bkjB-5e8yA:
26.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
GLU A 290
LEU A 305
THR A 325
HIS A 377
LEU A 386
ASP A 397
 STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
STU  A 601 (-3.9A)
STU  A 601 (-3.0A)
 1.00A 4c8bA-5e8yA:
17.9		 4c8bA-5e8yA:
27.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
LYS A 277
GLU A 290
LEU A 305
THR A 325
HIS A 377
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
STU  A 601 (-3.9A)
 0.66A 4c8bA-5e8yA:
17.9		 4c8bA-5e8yA:
27.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_B_0LIB1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
LYS A 277
GLU A 290
ILE A 304
LEU A 305
THR A 325
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
None
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.9A)
 0.66A 4c8bB-5e8yA:
18.1		 4c8bB-5e8yA:
27.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_B_0LIB1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
LYS A 277
ILE A 304
LEU A 305
THR A 325
HIS A 377
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
None
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
STU  A 601 (-3.9A)
 0.56A 4c8bB-5e8yA:
18.1		 4c8bB-5e8yA:
27.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4I41_A_MIXA500_1
(SERINE/THREONINE-PRO
TEIN KINASE PIM-1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
ASP A 379
LYS A 381
ASN A 384
LEU A 386
ASP A 397
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
None
None
STU  A 601 ( 4.9A)
STU  A 601 (-3.9A)
STU  A 601 (-3.0A)
 0.73A 4i41A-5e8yA:
16.7		 4i41A-5e8yA:
25.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4O0S_A_ADNA500_1
(AURORA KINASE A)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 11 GLY A 251
VAL A 258
ALA A 275
LYS A 277
LEU A 305
ASN A 384
LEU A 386
 STU  A 601 (-2.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 4.9A)
STU  A 601 (-3.9A)
 0.75A 4o0sA-5e8yA:
18.8		 4o0sA-5e8yA:
26.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4R7I_A_STIA1001_1
(MACROPHAGE
COLONY-STIMULATING
FACTOR 1 RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
LYS A 277
GLU A 290
THR A 325
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.9A)
 0.50A 4r7iA-5e8yA:
24.6		 4r7iA-5e8yA:
26.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 VAL A 258
ALA A 275
LYS A 277
LEU A 305
THR A 325
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
 0.43A 4rzvB-5e8yA:
24.7		 4rzvB-5e8yA:
27.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U0I_A_0LIA1001_2
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR
KIT,MAST/STEM CELL
GROWTH FACTOR
RECEPTOR KIT)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
LYS A 277
THR A 325
GLY A 331
HIS A 377
LEU A 386
CYH A 396
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
None
STU  A 601 (-3.9A)
STU  A 601 (-3.2A)
 0.52A 4u0iA-5e8yA:
24.9		 4u0iA-5e8yA:
28.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U0I_A_0LIA1001_2
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR
KIT,MAST/STEM CELL
GROWTH FACTOR
RECEPTOR KIT)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
LYS A 277
THR A 325
HIS A 377
LEU A 386
CYH A 396
ASP A 397
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.7A)
None
STU  A 601 (-3.9A)
STU  A 601 (-3.2A)
STU  A 601 (-3.0A)
 0.85A 4u0iA-5e8yA:
24.9		 4u0iA-5e8yA:
28.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WA9_B_AXIB9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
LYS A 277
THR A 325
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.86A 4wa9B-5e8yA:
19.8		 4wa9B-5e8yA:
27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WA9_B_AXIB9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
THR A 325
PHE A 327
GLY A 331
ASN A 384
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 ( 4.9A)
STU  A 601 (-3.9A)
 0.63A 4wa9B-5e8yA:
19.8		 4wa9B-5e8yA:
27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WKQ_A_IREA1101_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
LYS A 277
GLU A 290
LEU A 323
THR A 325
GLY A 331
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
None
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.61A 4wkqA-5e8yA:
26.8		 4wkqA-5e8yA:
25.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XEY_B_1N1B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
LYS A 277
THR A 325
PHE A 327
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.4A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.45A 4xeyB-5e8yA:
17.3		 4xeyB-5e8yA:
25.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XV2_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
LYS A 277
LEU A 305
THR A 325
ASP A 397
PHE A 398
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.0A)
None
 0.65A 4xv2A-5e8yA:
25.0		 4xv2A-5e8yA:
28.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XV2_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 ALA A 275
LYS A 277
LEU A 305
THR A 325
ASP A 397
PHE A 398
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.0A)
None
 0.59A 4xv2B-5e8yA:
25.2		 4xv2B-5e8yA:
28.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CSW_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
LYS A 277
LEU A 305
THR A 325
PHE A 398
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
 0.49A 5cswA-5e8yA:
24.8		 5cswA-5e8yA:
28.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CSW_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
LYS A 277
LEU A 305
THR A 325
PHE A 398
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
 0.58A 5cswB-5e8yA:
24.5		 5cswB-5e8yA:
28.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 VAL A 258
ALA A 275
LYS A 277
THR A 325
CYH A 396
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.2A)
 0.41A 5hesB-5e8yA:
20.3		 5hesB-5e8yA:
30.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HI2_A_BAXA801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 ALA A 275
LYS A 277
GLU A 290
LEU A 305
THR A 325
LEU A 361
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
 0.81A 5hi2A-5e8yA:
25.3		 5hi2A-5e8yA:
27.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HI2_A_BAXA801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 ALA A 275
LYS A 277
LEU A 305
THR A 325
LEU A 361
HIS A 377
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
None
None
 0.75A 5hi2A-5e8yA:
25.3		 5hi2A-5e8yA:
27.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 GLY A 253
VAL A 258
ALA A 275
LYS A 277
THR A 325
 STU  A 601 ( 3.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.7A)
 0.75A 5hieA-5e8yA:
25.0		 5hieA-5e8yA:
28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 PHE A 279
VAL A 258
ALA A 275
LYS A 277
LEU A 305
THR A 325
 None
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
 1.14A 5hieA-5e8yA:
25.0		 5hieA-5e8yA:
28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 GLY A 253
VAL A 258
ALA A 275
LYS A 277
THR A 325
 STU  A 601 ( 3.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.7A)
 0.75A 5hieB-5e8yA:
8.6		 5hieB-5e8yA:
28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 PHE A 279
VAL A 258
ALA A 275
LYS A 277
LEU A 305
THR A 325
 None
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
 1.14A 5hieB-5e8yA:
8.6		 5hieB-5e8yA:
28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_C_P06C801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 GLY A 251
GLY A 253
VAL A 258
ALA A 275
LYS A 277
LEU A 305
THR A 325
 STU  A 601 (-2.9A)
STU  A 601 ( 3.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
 0.83A 5hieC-5e8yA:
25.3		 5hieC-5e8yA:
28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_C_P06C801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 GLY A 251
PHE A 279
VAL A 258
ALA A 275
LYS A 277
LEU A 305
THR A 325
 STU  A 601 (-2.9A)
None
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
 1.10A 5hieC-5e8yA:
25.3		 5hieC-5e8yA:
28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_C_P06C801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 GLY A 251
VAL A 258
ALA A 275
LYS A 277
LEU A 305
THR A 325
ASP A 397
 STU  A 601 (-2.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.0A)
 0.64A 5hieC-5e8yA:
25.3		 5hieC-5e8yA:
28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_D_P06D801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		5 / 12 GLY A 253
VAL A 258
ALA A 275
LYS A 277
THR A 325
 STU  A 601 ( 3.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.7A)
 0.75A 5hieD-5e8yA:
25.0		 5hieD-5e8yA:
28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_D_P06D801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 PHE A 279
VAL A 258
ALA A 275
LYS A 277
LEU A 305
THR A 325
 None
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
 1.14A 5hieD-5e8yA:
25.0		 5hieD-5e8yA:
28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5I9Y_A_1N1A1001_1
(EPHRIN TYPE-A
RECEPTOR 2)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 ALA A 275
LYS A 277
GLU A 290
THR A 325
GLY A 331
LEU A 386
 STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.66A 5i9yA-5e8yA:
19.5		 5i9yA-5e8yA:
29.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VCY_A_DB8A401_1
(MEMBRANE-ASSOCIATED
TYROSINE- AND
THREONINE-SPECIFIC
CDC2-INHIBITORY
KINASE)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 VAL A 258
ALA A 275
LYS A 277
GLU A 290
LEU A 323
THR A 325
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
None
STU  A 601 ( 3.7A)
 0.62A 5vcyA-5e8yA:
23.3		 5vcyA-5e8yA:
25.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WAU_C_CHDC306_0
(CYTOCHROME C OXIDASE
SUBUNIT 3
CYTOCHROME C OXIDASE
SUBUNIT 7A1,
MITOCHONDRIAL)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		4 / 5 PHE A 255
PHE A 279
LEU A 323
PHE A 294
 None
 1.24A 5wauC-5e8yA:
2.0
5wauJ-5e8yA:
undetectable		 5wauC-5e8yA:
20.43
5wauJ-5e8yA:
11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WAU_C_CHDC308_0
(CYTOCHROME C OXIDASE
SUBUNIT 3
CYTOCHROME C OXIDASE
SUBUNIT 7A1,
MITOCHONDRIAL)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		4 / 5 PHE A 255
PHE A 279
LEU A 323
PHE A 294
 None
 1.22A 5wauc-5e8yA:
2.7
5wauj-5e8yA:
undetectable		 5wauc-5e8yA:
20.43
5wauj-5e8yA:
11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5XDQ_C_CHDC308_0
(CYTOCHROME C OXIDASE
SUBUNIT 3
CYTOCHROME C OXIDASE
SUBUNIT 7A1,
MITOCHONDRIAL)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		4 / 5 PHE A 255
PHE A 279
LEU A 323
PHE A 294
 None
 1.15A 5xdqC-5e8yA:
2.0
5xdqJ-5e8yA:
undetectable		 5xdqC-5e8yA:
20.43
5xdqJ-5e8yA:
11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5XDQ_P_CHDP306_0
(CYTOCHROME C OXIDASE
SUBUNIT 3
CYTOCHROME C OXIDASE
SUBUNIT 7A1,
MITOCHONDRIAL)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		4 / 5 PHE A 255
PHE A 279
LEU A 323
PHE A 294
 None
 1.20A 5xdqP-5e8yA:
2.3
5xdqW-5e8yA:
undetectable		 5xdqP-5e8yA:
20.43
5xdqW-5e8yA:
11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_B_IREB401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 ALA A 275
GLU A 290
LEU A 323
GLY A 331
LEU A 386
CYH A 396
ASP A 397
 STU  A 601 (-3.1A)
STU  A 601 ( 3.8A)
None
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
STU  A 601 (-3.2A)
STU  A 601 (-3.0A)
 0.92A 5y7zB-5e8yA:
24.6		 5y7zB-5e8yA:
12.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5YU9_A_1E8A1101_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 GLY A 251
VAL A 258
ALA A 275
LYS A 277
LEU A 323
LEU A 386
 STU  A 601 (-2.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
None
STU  A 601 (-3.9A)
 0.63A 5yu9A-5e8yA:
18.3		 5yu9A-5e8yA:
13.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5YU9_B_1E8B1101_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		6 / 12 GLY A 251
VAL A 258
ALA A 275
LYS A 277
LEU A 323
LEU A 386
 STU  A 601 (-2.9A)
STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
None
STU  A 601 (-3.9A)
 0.68A 5yu9B-5e8yA:
18.6		 5yu9B-5e8yA:
13.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BSD_A_1N1A901_0
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 5e8y TGF-BETA RECEPTOR
TYPE-2
(Homo
sapiens) 		7 / 12 VAL A 258
ALA A 275
LYS A 277
GLU A 290
THR A 325
GLY A 331
LEU A 386
 STU  A 601 (-4.0A)
STU  A 601 (-3.1A)
STU  A 601 (-2.4A)
STU  A 601 ( 3.8A)
STU  A 601 ( 3.7A)
STU  A 601 (-3.5A)
STU  A 601 (-3.9A)
 0.60A 6bsdA-5e8yA:
24.2		 6bsdA-5e8yA:
14.55